Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Drug-drug Interactions between Atorvastatin and Telmisartan

Atorvastatin과 Telmisartan의 약물상호작용

  • Received : 2013.08.07
  • Accepted : 2013.11.27
  • Published : 2013.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Atorvastatin, a HMG-CoA reductase inhibitor is widely prescribed in hyperlipidemic patients and telmisartan, an angiotensin receptor blocker is frequently used in the treatment of hypertension. Both drugs are substrates of organic anion transporting polypeptide (OATP) expressed in basolateral membrane in the liver, and undergo high first pass metabolism. Therefore, OATP-mediated hepatic uptake is important for disposition and metabolism of these drugs. The present study was designed to investigate the pharmacokinetic interactions between atorvastatin and telmisartan in rats. Method: Young adult SD rats were divided into three groups (n=6, each) and atorvastatin (10 mg/kg) and telmisartan (4 mg/kg) were orally given alone and together. Heparinized blood was serially taken and plasma concentrations of both drugs were measured using HPLC-MS/MS. Pharmacokinetic parameters of two drugs were calculated. Results: No significant pharmacokinetic change was found except a delay of time to peak of telmisartan when administered with atorvastatin. Each drug at the present dosage seemed to be insufficient to alter the pharmacokinetic parameters of its counterpart drug. Conclusion: Conclusively, co-administration of atorvastatin and telmisartan may lead to negligible clinical consequences.

Keywords

References

  1. Stangier J, Su CA, Roth W. Pharmacokinetics of Orally and Intravenously Administered Telmisartan in Healthy Young and Elderly Volunteers and in Hypertensive Patients. J int Med Res 2000; 28: 149-67. https://doi.org/10.1177/147323000002800401
  2. Wienen W, Entzeroth M, Van Meel JCA, et al. A Review on Telmisartan: A Novel, Long-Acting Angiotensin IIReceptor Antagonist. Cardiovasc Drug Rev 2000; 18: 127-54.
  3. Ren S, Zeng J, Mei Y, et al. Discovery and Characterization of Novel, Potent, and Selective Cytochrome P450 2J2 Inhibitors. Drug Metab Dispos 2013; 41: 60-71. https://doi.org/10.1124/dmd.112.048264
  4. Stangier J, Schmid J, Trck D, et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol 2000; 40: 1312-22.
  5. Lennerns H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003; 42: 1141-60. https://doi.org/10.2165/00003088-200342130-00005
  6. Kearney AS, Crawford LF, Mehta SC, et al. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm Res 1993; 10: 1461-5. https://doi.org/10.1023/A:1018923325359
  7. Grube M, Kck K, Oswald S, et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 2006; 80: 607-20. https://doi.org/10.1016/j.clpt.2006.09.010
  8. Kalliokoski A. and Niemi M. REVIEW: Impact of OATP transporters on pharmacokinetics Br J Pharmacol 2009; 158: 693-705. https://doi.org/10.1111/j.1476-5381.2009.00430.x
  9. Ishiguro N, Maeda K, Kishimoto W, et al. Predominant contribution of OATP1b3 to the hepatic uptake of telmisartan, An angiotensin II receptor antagonist, in humans. Drug Metab Dispos 2006; 34: 1109-15. https://doi.org/10.1124/dmd.105.009175
  10. Macwan JS, Ionita IA, Dostalek M, et al. Development and validation of a sensitive, simple, and rapid method for simultaneous quantitation of atorvastatin and its acid and lactone metabolites by liquid chromatography-tandem mass spectrometry(LC-MS/MS) Anal Bioanal Chem 2011; 400: 423-33. https://doi.org/10.1007/s00216-011-4804-y
  11. Herv F, Urien S, Albengres E, et al. Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. Clin Pharmacokinet 1944; 26: 44-58.
  12. Vats R, Varanasi KV, Arla R, et al. Effect of multidose cilostazol on pharmacokinetic and lipid profile of atorvastatin in male Wistar rats. J Pharm Pharmacol 2012; 64: 1638-45. https://doi.org/10.1111/j.2042-7158.2012.01542.x
  13. Karlgren M, Vildhede A, Norinder U, et al. Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug-Drug Interactions. J Med Chem 2012; 55: 4740-63. https://doi.org/10.1021/jm300212s
  14. Lins RL, Matthys KE, Verpooten GA, et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant 2003; 18: 967-76. https://doi.org/10.1093/ndt/gfg048
  15. Lau YY, Okochi H, Huang Y, et al. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 2006; 34: 1175-81. https://doi.org/10.1124/dmd.105.009076
  16. DeGorter MK, Ho RH, Leake BF, et al. Interaction of three regiospecific amino acid residues is required for OATP1B1 gain of OATP1B3 substrate specificity. Mol Pharm 2012; 9: 986-95. https://doi.org/10.1021/mp200629s
  17. Kalliokoski A, Backman JT, Kurkinen KJ, et al. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther 2008; 84: 488-96. https://doi.org/10.1038/clpt.2008.74
  18. Hermann M, Asberg A, Christensen H, et al. Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clin Pharmacol Ther 2004; 76: 388-91. https://doi.org/10.1016/j.clpt.2004.07.008
  19. Lemahieu WP, Hermann M, Asberg A, et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 2005; 5: 2236-43. https://doi.org/10.1111/j.1600-6143.2005.01005.x
  20. Backman JT, Luurila H, Neuvonen M, et al. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 2005; 78: 154-67. https://doi.org/10.1016/j.clpt.2005.04.007
  21. Lau YY, Huang Y, Frassetto L, et al. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 2007; 81: 194-204. https://doi.org/10.1038/sj.clpt.6100038
  22. Yoon H, Osun B. Drug interaction of warfarin with simvastatin/gemfibrozil: high levels of ALT/AST, rhabdomyolysis and acute renal failure. Kor J Clin Pharm 2011; 21: 270-5.
  23. Choi MK, Bang JS, Lee YJ. Patterns of over-the-counter drug use and interactions between over-the counter drugs and prescription drugs in adults visiting a community pharmacy. Kor J Clin Pharm 2013; 23: 49-56.
  24. Miura M, Satoh S, Kagaya H, et al. Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. J Clin Pharm Ther 2009; 34: 683-92. https://doi.org/10.1111/j.1365-2710.2009.01053.x
  25. Kataoka M, Takashima T, Shingaki T, et al. Dynamic analysis of GI absorption and hepatic distribution processes of telmisartan in rats using positron emission tomography. Pharm Res 2012; 29: 2419-31. https://doi.org/10.1007/s11095-012-0768-7
  26. Hao K, Chen YC, Cao YG, et al. Pharmacokineticpharmacodynamic modeling of telmisartan using an indirect response model in spontaneously hypertensive rats. Acta Pharmacol Sin 2007; 28: 738-48. https://doi.org/10.1111/j.1745-7254.2007.00556.x